Modality
Small Molecule
MOA
Anti-Tau
Target
CFTR
Pathway
Autophagy
Wilms
Development Pipeline
Preclinical
~Feb 2020
→ ~May 2021
Phase 1
~Aug 2021
→ ~Nov 2022
Phase 2
~Feb 2023
→ ~May 2024
Phase 3
Aug 2024
→ Jun 2027
Phase 3Current
NCT08510125
1,559 pts·Wilms
2024-08→2027-06·Recruiting
1,559 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-06-031.2y awayPh3 Readout· Wilms
Trial Timeline
Q42025Q2Q3Q42026Q2Q3Q42027Q2
P3
Recruit…
Catalysts
Ph3 Readout
2027-06-03 · 1.2y away
Wilms
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08510125 | Phase 3 | Wilms | Recruiting | 1559 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| NVS-5439 | Novartis | Preclinical | BET | |
| Datoglumide | AbbVie | Approved | CFTR | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| BGN-3305 | BeiGene | Phase 2 | BCMA | |
| Sovarelsin | BioMarin | Phase 2 | CFTR |